

### Remarks

Applicants appreciate the Examiner's allowance of claims 36-41 and 66.

#### Correction of Priority Data

The specification has been amended to reflect the status of parent application Serial No. 09/245,331.

#### The Rejection of Claims 81-88, 91, 92, and 94-105 Under 35 U.S.C. § 112, second paragraph


Claims 81-88, 91, 92, and 94-105 stand rejected under 35 U.S.C. § 112, second paragraph. Applicants respectfully traverse the rejection.

The Office Action states that the phrases “form of a leukotoxin molecule” and “wherein the second source comprises the form of the leukotoxin molecule,” which are recited in independent claims 81, 91, and 95, are confusing. As suggested in the Office Action, Applicants have amended claims 81, 91, and 95 to recite the Markush group previously recited in claims 102-104, which have been canceled. The feed of claim 81 and the vaccine formulations recited in claims 91 and 95 comprise (1) a killed *P. haemolytica* bacterium which expressed a deletion mutant leukotoxin molecule when it was alive and (2) the deletion mutant molecule in the form of a purified protein or in a preparation selected from the group consisting of a bacterial lysate, a bacterial extract, and a culture supernatant. The amendments add no new matter.

Applicants believe claims 81-88, 91, 92, and 94-105 as amended are clear and definite.  
Applicants respectfully request withdrawal of the rejection.

Respectfully submitted,  
BANNER & WITCOFF, LTD.

Date: November 8, 2004

By:   
Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907